Forte Biosciences (FBRX)
Develops the anti-CD122 antibody candidate FB102 for autoimmune and autoimmune-related diseases.
$76.99
At close0.00 (0.00%)
Something off on this page? Send us feedback.
Next report
Nov 13, 2026
in 71 days
EPS estimate
−$0.90
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$1.37−$0.96−$0.99−$1.45−$1.24−$0.97−$0.97Pending
Estimate−$0.89−$1.21−$1.04−$1.42−$1.16−$1.03−$0.88−$0.90
Surprise−53.9%+20.7%+4.8%−2.1%−6.9%+5.8%−10.4%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.90 | — | — |
| Aug 2026 | −$0.88 | −$0.97 | −10.4% |
| Aug 2026 | −$1.03 | −$0.97 | +5.8% |
| May 2026 | −$1.16 | −$1.24 | −6.9% |
| Mar 2026 | −$1.42 | −$1.45 | −2.1% |
The latest year is open to everyone — the 36 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Apr 2017 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.90 | — | — | — | — | — | — |
| Aug 12, 2026 | −$0.88 | −$0.97 | −10.4% | — | — | — | +0.1% |
| Aug 11, 2026 | −$1.03 | −$0.97 | +5.8% | — | — | — | +0.1% |
| May 11, 2026 | −$1.16 | −$1.24 | −6.9% | — | — | — | −6.6% |
| Mar 31, 2026 | −$1.42 | −$1.45 | −2.1% | — | — | — | −4.0% |
The latest year is open to everyone — the 36 quarters behind it read with an account. Sign in | |||||||
| Nov 14, 2025 | |||||||
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 24, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 13, 2024 | |||||||
| Mar 18, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| Apr 23, 2020 | |||||||
| Feb 27, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 27, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 10, 2018 | |||||||
| Mar 8, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 23, 2017 | |||||||
| Apr 13, 2017 | — | — | — | — | — | — | — |